Puma Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Puma Biotechnology has a total shareholder equity of $53.4M and total debt of $99.7M, which brings its debt-to-equity ratio to 186.5%. Its total assets and total liabilities are $230.5M and $177.1M respectively. Puma Biotechnology's EBIT is $33.3M making its interest coverage ratio 3.1. It has cash and short-term investments of $95.9M.
Key information
186.5%
Debt to equity ratio
US$99.66m
Debt
| Interest coverage ratio | 3.1x |
| Cash | US$95.94m |
| Equity | US$53.44m |
| Total liabilities | US$177.09m |
| Total assets | US$230.53m |
Recent financial health updates
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Recent updates
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Puma Bio: Still Worthy Of Consideration After Earnings Surprise
Mar 08Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball
Aug 13Financial Position Analysis
Short Term Liabilities: PBYI's short term assets ($156.2M) exceed its short term liabilities ($99.4M).
Long Term Liabilities: PBYI's short term assets ($156.2M) exceed its long term liabilities ($77.7M).
Debt to Equity History and Analysis
Debt Level: PBYI's net debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: PBYI's debt to equity ratio has reduced from 442.7% to 186.5% over the past 5 years.
Debt Coverage: PBYI's debt is well covered by operating cash flow (27.1%).
Interest Coverage: PBYI's interest payments on its debt are well covered by EBIT (3.1x coverage).